Search Results For:
- Issue:
- Business model | Product supply
(Click + to show provisions)
Agreement title
Effective date
Partner type
Technology
Development stage
European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
2020
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
2020
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
UK Secretary of State - AstraZeneca, COVID-19 Vaccine Supply Agreement
2020
Government
Industry
Industry
Vaccine
Commercialization
US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement
2020
Government
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Early clinical (through Phase 2)
Late clinical (Phase 3)
AXA Prime Impact Master Fund - Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement
2020
Funder
Industry
Industry
Diagnostic
Drug
Drug
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
Biological E - Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
2021
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
Gates Foundation - Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
2021
Funder
Industry
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
CEPI - Dynavax, COVID-19 Material Reservation Agreement
2021
Funder
Industry
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
2021
Funder
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Early clinical (through Phase 2)
CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement
2021
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
DNDi Template Development Collaboration and License Agreement
2023
Academic institution
Industry
Product development partnership
Industry
Product development partnership
Drug
Early clinical (through Phase 2)
Late clinical (Phase 3)
Late clinical (Phase 3)
DNDi - BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement
2009
Industry
Product development partnership
Product development partnership
Drug
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
DNDi/GARDP - Entasis, Gonorrhoea Medication, Collaboration Agreement
2017
Industry
Product development partnership
Product development partnership
Drug
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
Fiocruz - AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
2021
Government
Industry
Industry
Vaccine
Commercialization
Gavi Alliance - Novavax, COVID-19 Vaccine Advance Purchase Agreement
2021
Industry
Multilateral organization
Multilateral organization
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
2020
Industry
Drug
Vaccine
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Merck - MPP, Molnupiravir License Agreement
2021
Industry
Multilateral organization
Multilateral organization
Drug
Late clinical (Phase 3)
Commercialization
Commercialization
US Government - Ology Bioservices, COVID-19 Plasmid Procurement Agreement
2020
Government
Industry
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
National Health Service (NHS) – Pfizer/Shionogi, Antibiotic Supply Agreement
2022
Government
Industry
Industry
Drug
Commercialization
NIH - GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
2020
Government
Industry
Industry
Vaccine
Preclinical
Commercialization
Commercialization
NIH - MPP, COVID-19 Patent and Biological Material License Agreement
2022
Government
Multilateral organization
Multilateral organization
Diagnostic
Drug
Vaccine
Drug
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
CEPI - Novavax, COVID-19 Vaccine Funding Agreement
2020
Funder
Industry
Industry
Vaccine
Commercialization
Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
2020
Industry
Vaccine
Commercialization
Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
2021
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
2021
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
2021
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
2020
Government
Industry
Industry
Drug
Late clinical (Phase 3)
Commercialization
Commercialization
Shionogi - GARDP, Cefiderocol License Agreement
2022
Industry
Product development partnership
Product development partnership
Drug
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
University of Washington - Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement
2021
Academic institution
Multilateral organization
Multilateral organization
Drug
Preclinical
US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
2020
Government
Industry
Industry
Vaccine
Commercialization
UK Secretary of State - Roche, REGN-COV2 Supply Agreement
2021
Government
Industry
Industry
Drug
Late clinical (Phase 3)
Commercialization
Commercialization
GHIAA2019\MapguideSearch Object
(
[search_parameters] => Array
(
[issue] => Array
(
[0] => supply-purchase-of-products
)
)
[filters] => Array
(
[provision] => Array
(
[issue] => Array
(
[0] => supply-purchase-of-products
)
)
)
[child_filters] => Array
(
)
[agreement_args] =>
[provision_args] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
[tax_query] => Array
(
[0] => Array
(
[taxonomy] => issue
[field] => slug
[terms] => Array
(
[0] => supply-purchase-of-products
)
)
)
)
[text_agreement_args] =>
[text_provision_args] =>
[agreement_ids] => Array
(
)
[agreement_q_rslts] =>
[provision_q_rslts] => WP_Query Object
(
[query] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
[tax_query] => Array
(
[0] => Array
(
[taxonomy] => issue
[field] => slug
[terms] => Array
(
[0] => supply-purchase-of-products
)
)
)
)
[query_vars] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
[tax_query] => Array
(
[0] => Array
(
[taxonomy] => issue
[field] => slug
[terms] => Array
(
[0] => supply-purchase-of-products
)
)
)
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[s] =>
[sentence] =>
[title] =>
[fields] =>
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[search_columns] => Array
(
)
[ignore_sticky_posts] =>
[suppress_filters] =>
[cache_results] => 1
[update_post_term_cache] => 1
[update_menu_item_cache] =>
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] => 1
[comments_per_page] => 50
[no_found_rows] =>
[taxonomy] => issue
[term] => supply-purchase-of-products
[order] => DESC
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
[0] => Array
(
[taxonomy] => issue
[terms] => Array
(
[0] => supply-purchase-of-products
)
[field] => slug
[operator] => IN
[include_children] => 1
)
)
[relation] => AND
[table_aliases:protected] => Array
(
[0] => wpry_term_relationships
)
[queried_terms] => Array
(
[issue] => Array
(
[terms] => Array
(
[0] => supply-purchase-of-products
)
[field] => slug
)
)
[primary_table] => wpry_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] =>
SELECT wpry_posts.*
FROM wpry_posts LEFT JOIN wpry_term_relationships ON (wpry_posts.ID = wpry_term_relationships.object_id)
WHERE 1=1 AND (
wpry_term_relationships.term_taxonomy_id IN (268)
) AND ((wpry_posts.post_type = 'provision_document' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled')))
GROUP BY wpry_posts.ID
ORDER BY wpry_posts.post_date DESC
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 9877
[post_author] => 5
[post_date] => 2023-04-19 11:54:25
[post_date_gmt] => 2023-04-19 11:54:25
[post_content] =>
[post_title] => DNDi Template Development Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => dndi-template-development-collaboration-and-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2023-04-20 14:10:10
[post_modified_gmt] => 2023-04-20 14:10:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=9877
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 9015
[post_author] => 5
[post_date] => 2023-03-02 12:13:42
[post_date_gmt] => 2023-03-02 12:13:42
[post_content] =>
[post_title] => National Health Service (NHS) – Pfizer/Shionogi, Antibiotic Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2023-03-02 12:13:42
[post_modified_gmt] => 2023-03-02 12:13:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=9015
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 8131
[post_author] => 5
[post_date] => 2022-12-12 09:57:36
[post_date_gmt] => 2022-12-12 09:57:36
[post_content] =>
[post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2023-04-28 13:38:50
[post_modified_gmt] => 2023-04-28 13:38:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8131
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 6323
[post_author] => 5
[post_date] => 2022-10-27 09:37:11
[post_date_gmt] => 2022-10-27 09:37:11
[post_content] =>
[post_title] => DNDi – BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2023-05-08 13:50:34
[post_modified_gmt] => 2023-05-08 13:50:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=6323
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 5778
[post_author] => 5
[post_date] => 2022-09-14 11:49:49
[post_date_gmt] => 2022-09-14 11:49:49
[post_content] =>
[post_title] => AXA Prime Impact Master Fund – Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2023-04-28 13:16:48
[post_modified_gmt] => 2023-04-28 13:16:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5778
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[5] => WP_Post Object
(
[ID] => 5653
[post_author] => 5
[post_date] => 2022-08-25 12:56:30
[post_date_gmt] => 2022-08-25 12:56:30
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2023-03-30 14:41:50
[post_modified_gmt] => 2023-03-30 14:41:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5653
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[6] => WP_Post Object
(
[ID] => 5594
[post_author] => 5
[post_date] => 2022-08-11 12:13:32
[post_date_gmt] => 2022-08-11 12:13:32
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2023-05-01 14:22:41
[post_modified_gmt] => 2023-05-01 14:22:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5594
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[7] => WP_Post Object
(
[ID] => 5278
[post_author] => 5
[post_date] => 2022-07-08 10:25:20
[post_date_gmt] => 2022-07-08 10:25:20
[post_content] =>
[post_title] => Shionogi – GARDP, Cefiderocol License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => shionogi-gardp-cefiderocol-license-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2023-05-01 14:41:51
[post_modified_gmt] => 2023-05-01 14:41:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5278
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[8] => WP_Post Object
(
[ID] => 5123
[post_author] => 5
[post_date] => 2022-06-29 15:28:35
[post_date_gmt] => 2022-06-29 15:28:35
[post_content] =>
[post_title] => NIH - MPP, COVID-19 Patent and Biological Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2023-04-05 12:27:11
[post_modified_gmt] => 2023-04-05 12:27:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5123
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[9] => WP_Post Object
(
[ID] => 4884
[post_author] => 5
[post_date] => 2022-06-08 07:54:05
[post_date_gmt] => 2022-06-08 07:54:05
[post_content] =>
[post_title] => Entasis - DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-09 12:24:23
[post_modified_gmt] => 2022-06-09 12:24:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4884
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[10] => WP_Post Object
(
[ID] => 4148
[post_author] => 5
[post_date] => 2022-04-12 08:59:45
[post_date_gmt] => 2022-04-12 08:59:45
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2023-05-01 14:25:17
[post_modified_gmt] => 2023-05-01 14:25:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4148
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[11] => WP_Post Object
(
[ID] => 4213
[post_author] => 5
[post_date] => 2022-03-03 10:54:01
[post_date_gmt] => 2022-03-03 10:54:01
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-31 15:05:32
[post_modified_gmt] => 2022-05-31 15:05:32
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4213
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[12] => WP_Post Object
(
[ID] => 4131
[post_author] => 5
[post_date] => 2022-01-29 16:21:19
[post_date_gmt] => 2022-01-29 16:21:19
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2023-04-28 13:35:36
[post_modified_gmt] => 2023-04-28 13:35:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4131
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[13] => WP_Post Object
(
[ID] => 4080
[post_author] => 5
[post_date] => 2022-01-11 08:32:58
[post_date_gmt] => 2022-01-11 08:32:58
[post_content] =>
[post_title] => University of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-11 15:17:30
[post_modified_gmt] => 2022-01-11 15:17:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4080
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[14] => WP_Post Object
(
[ID] => 4041
[post_author] => 5
[post_date] => 2021-12-27 16:28:21
[post_date_gmt] => 2021-12-27 16:28:21
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2023-03-21 11:33:53
[post_modified_gmt] => 2023-03-21 11:33:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4041
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[15] => WP_Post Object
(
[ID] => 4007
[post_author] => 5
[post_date] => 2021-12-14 08:51:32
[post_date_gmt] => 2021-12-14 08:51:32
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-14 08:51:44
[post_modified_gmt] => 2021-12-14 08:51:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4007
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[16] => WP_Post Object
(
[ID] => 3898
[post_author] => 5
[post_date] => 2021-11-22 11:02:44
[post_date_gmt] => 2021-11-22 11:02:44
[post_content] =>
[post_title] => Merck – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-27 14:52:13
[post_modified_gmt] => 2023-01-27 14:52:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3898
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[17] => WP_Post Object
(
[ID] => 3875
[post_author] => 5
[post_date] => 2021-11-18 14:43:39
[post_date_gmt] => 2021-11-18 14:43:39
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2023-05-01 14:30:10
[post_modified_gmt] => 2023-05-01 14:30:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3875
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[18] => WP_Post Object
(
[ID] => 3855
[post_author] => 5
[post_date] => 2021-11-05 13:10:25
[post_date_gmt] => 2021-11-05 13:10:25
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2023-04-27 08:19:07
[post_modified_gmt] => 2023-04-27 08:19:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3855
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[19] => WP_Post Object
(
[ID] => 3809
[post_author] => 5
[post_date] => 2021-09-10 12:11:12
[post_date_gmt] => 2021-09-10 12:11:12
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-03 13:54:22
[post_modified_gmt] => 2022-10-03 13:54:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3809
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[20] => WP_Post Object
(
[ID] => 3786
[post_author] => 5
[post_date] => 2021-09-09 13:20:21
[post_date_gmt] => 2021-09-09 13:20:21
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2023-05-02 13:28:45
[post_modified_gmt] => 2023-05-02 13:28:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3786
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[21] => WP_Post Object
(
[ID] => 3696
[post_author] => 5
[post_date] => 2021-08-19 14:23:22
[post_date_gmt] => 2021-08-19 14:23:22
[post_content] =>
[post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ati-regeneron-covid-19-antibodies-manufacturing-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-15 07:52:58
[post_modified_gmt] => 2022-12-15 07:52:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3696
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[22] => WP_Post Object
(
[ID] => 3495
[post_author] => 5
[post_date] => 2021-08-10 13:06:45
[post_date_gmt] => 2021-08-10 13:06:45
[post_content] =>
[post_title] => US Department of Defense – Moderna, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => dod-moderna-covid-19-vaccine-supply-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-15 09:00:22
[post_modified_gmt] => 2022-12-15 09:00:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3495
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[23] => WP_Post Object
(
[ID] => 3414
[post_author] => 5
[post_date] => 2021-06-30 18:54:43
[post_date_gmt] => 2021-06-30 18:54:43
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-27 12:29:49
[post_modified_gmt] => 2022-06-27 12:29:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3414
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[24] => WP_Post Object
(
[ID] => 3352
[post_author] => 5
[post_date] => 2021-06-30 13:24:49
[post_date_gmt] => 2021-06-30 13:24:49
[post_content] =>
[post_title] => US Government - Ology Bioservices, COVID-19 Plasmid Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-12 13:47:30
[post_modified_gmt] => 2022-10-12 13:47:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3352
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[25] => WP_Post Object
(
[ID] => 3302
[post_author] => 6
[post_date] => 2021-06-30 09:21:45
[post_date_gmt] => 2021-06-30 09:21:45
[post_content] =>
[post_title] => UK Secretary of State - Roche, REGN-COV2 Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => 3302
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-15 09:07:23
[post_modified_gmt] => 2022-12-15 09:07:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3302
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[26] => WP_Post Object
(
[ID] => 3217
[post_author] => 6
[post_date] => 2021-06-28 12:14:37
[post_date_gmt] => 2021-06-28 12:14:37
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-15 09:11:47
[post_modified_gmt] => 2022-12-15 09:11:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3217
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[27] => WP_Post Object
(
[ID] => 3121
[post_author] => 6
[post_date] => 2021-06-03 14:26:32
[post_date_gmt] => 2021-06-03 14:26:32
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-15 09:13:08
[post_modified_gmt] => 2022-12-15 09:13:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3121
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[28] => WP_Post Object
(
[ID] => 2949
[post_author] => 6
[post_date] => 2021-05-28 18:52:06
[post_date_gmt] => 2021-05-28 18:52:06
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-15 09:37:27
[post_modified_gmt] => 2022-12-15 09:37:27
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2949
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[29] => WP_Post Object
(
[ID] => 2540
[post_author] => 5
[post_date] => 2021-03-12 18:12:48
[post_date_gmt] => 2021-03-12 18:12:48
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-15 09:38:53
[post_modified_gmt] => 2022-12-15 09:38:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2540
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[30] => WP_Post Object
(
[ID] => 2471
[post_author] => 5
[post_date] => 2021-01-25 13:08:02
[post_date_gmt] => 2021-01-25 13:08:02
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-15 09:39:40
[post_modified_gmt] => 2022-12-15 09:39:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2471
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 31
[current_post] => -1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 9877
[post_author] => 5
[post_date] => 2023-04-19 11:54:25
[post_date_gmt] => 2023-04-19 11:54:25
[post_content] =>
[post_title] => DNDi Template Development Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => dndi-template-development-collaboration-and-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2023-04-20 14:10:10
[post_modified_gmt] => 2023-04-20 14:10:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=9877
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 31
[max_num_pages] => 0
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] => 1
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] => 1
[is_search] =>
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] =>
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] => 1
[query_vars_hash:WP_Query:private] => 0f0add711492f97f5eeeddbd48ceac0b
[query_vars_changed:WP_Query:private] =>
[thumbnails_cached] =>
[allow_query_attachment_by_filename:protected] =>
[stopwords:WP_Query:private] =>
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
)
[text_agreement_q_rslts] =>
[text_provision_q_rslts] =>
[provisions] => Array
(
[0] => WP_Post Object
(
[ID] => 9877
[post_author] => 5
[post_date] => 2023-04-19 11:54:25
[post_date_gmt] => 2023-04-19 11:54:25
[post_content] =>
[post_title] => DNDi Template Development Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => dndi-template-development-collaboration-and-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2023-04-20 14:10:10
[post_modified_gmt] => 2023-04-20 14:10:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=9877
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 9015
[post_author] => 5
[post_date] => 2023-03-02 12:13:42
[post_date_gmt] => 2023-03-02 12:13:42
[post_content] =>
[post_title] => National Health Service (NHS) – Pfizer/Shionogi, Antibiotic Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2023-03-02 12:13:42
[post_modified_gmt] => 2023-03-02 12:13:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=9015
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 8131
[post_author] => 5
[post_date] => 2022-12-12 09:57:36
[post_date_gmt] => 2022-12-12 09:57:36
[post_content] =>
[post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2023-04-28 13:38:50
[post_modified_gmt] => 2023-04-28 13:38:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8131
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 6323
[post_author] => 5
[post_date] => 2022-10-27 09:37:11
[post_date_gmt] => 2022-10-27 09:37:11
[post_content] =>
[post_title] => DNDi – BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2023-05-08 13:50:34
[post_modified_gmt] => 2023-05-08 13:50:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=6323
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 5778
[post_author] => 5
[post_date] => 2022-09-14 11:49:49
[post_date_gmt] => 2022-09-14 11:49:49
[post_content] =>
[post_title] => AXA Prime Impact Master Fund – Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2023-04-28 13:16:48
[post_modified_gmt] => 2023-04-28 13:16:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5778
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[5] => WP_Post Object
(
[ID] => 5653
[post_author] => 5
[post_date] => 2022-08-25 12:56:30
[post_date_gmt] => 2022-08-25 12:56:30
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2023-03-30 14:41:50
[post_modified_gmt] => 2023-03-30 14:41:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5653
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[6] => WP_Post Object
(
[ID] => 5594
[post_author] => 5
[post_date] => 2022-08-11 12:13:32
[post_date_gmt] => 2022-08-11 12:13:32
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2023-05-01 14:22:41
[post_modified_gmt] => 2023-05-01 14:22:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5594
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[7] => WP_Post Object
(
[ID] => 5278
[post_author] => 5
[post_date] => 2022-07-08 10:25:20
[post_date_gmt] => 2022-07-08 10:25:20
[post_content] =>
[post_title] => Shionogi – GARDP, Cefiderocol License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => shionogi-gardp-cefiderocol-license-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2023-05-01 14:41:51
[post_modified_gmt] => 2023-05-01 14:41:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5278
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[8] => WP_Post Object
(
[ID] => 5123
[post_author] => 5
[post_date] => 2022-06-29 15:28:35
[post_date_gmt] => 2022-06-29 15:28:35
[post_content] =>
[post_title] => NIH - MPP, COVID-19 Patent and Biological Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2023-04-05 12:27:11
[post_modified_gmt] => 2023-04-05 12:27:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5123
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[9] => WP_Post Object
(
[ID] => 4884
[post_author] => 5
[post_date] => 2022-06-08 07:54:05
[post_date_gmt] => 2022-06-08 07:54:05
[post_content] =>
[post_title] => Entasis - DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-09 12:24:23
[post_modified_gmt] => 2022-06-09 12:24:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4884
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[10] => WP_Post Object
(
[ID] => 4148
[post_author] => 5
[post_date] => 2022-04-12 08:59:45
[post_date_gmt] => 2022-04-12 08:59:45
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2023-05-01 14:25:17
[post_modified_gmt] => 2023-05-01 14:25:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4148
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[11] => WP_Post Object
(
[ID] => 4213
[post_author] => 5
[post_date] => 2022-03-03 10:54:01
[post_date_gmt] => 2022-03-03 10:54:01
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-31 15:05:32
[post_modified_gmt] => 2022-05-31 15:05:32
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4213
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[12] => WP_Post Object
(
[ID] => 4131
[post_author] => 5
[post_date] => 2022-01-29 16:21:19
[post_date_gmt] => 2022-01-29 16:21:19
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2023-04-28 13:35:36
[post_modified_gmt] => 2023-04-28 13:35:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4131
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[13] => WP_Post Object
(
[ID] => 4080
[post_author] => 5
[post_date] => 2022-01-11 08:32:58
[post_date_gmt] => 2022-01-11 08:32:58
[post_content] =>
[post_title] => University of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-11 15:17:30
[post_modified_gmt] => 2022-01-11 15:17:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4080
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[14] => WP_Post Object
(
[ID] => 4041
[post_author] => 5
[post_date] => 2021-12-27 16:28:21
[post_date_gmt] => 2021-12-27 16:28:21
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2023-03-21 11:33:53
[post_modified_gmt] => 2023-03-21 11:33:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4041
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[15] => WP_Post Object
(
[ID] => 4007
[post_author] => 5
[post_date] => 2021-12-14 08:51:32
[post_date_gmt] => 2021-12-14 08:51:32
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-14 08:51:44
[post_modified_gmt] => 2021-12-14 08:51:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4007
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[16] => WP_Post Object
(
[ID] => 3898
[post_author] => 5
[post_date] => 2021-11-22 11:02:44
[post_date_gmt] => 2021-11-22 11:02:44
[post_content] =>
[post_title] => Merck – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-27 14:52:13
[post_modified_gmt] => 2023-01-27 14:52:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3898
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[17] => WP_Post Object
(
[ID] => 3875
[post_author] => 5
[post_date] => 2021-11-18 14:43:39
[post_date_gmt] => 2021-11-18 14:43:39
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2023-05-01 14:30:10
[post_modified_gmt] => 2023-05-01 14:30:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3875
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[18] => WP_Post Object
(
[ID] => 3855
[post_author] => 5
[post_date] => 2021-11-05 13:10:25
[post_date_gmt] => 2021-11-05 13:10:25
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2023-04-27 08:19:07
[post_modified_gmt] => 2023-04-27 08:19:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3855
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[19] => WP_Post Object
(
[ID] => 3809
[post_author] => 5
[post_date] => 2021-09-10 12:11:12
[post_date_gmt] => 2021-09-10 12:11:12
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-03 13:54:22
[post_modified_gmt] => 2022-10-03 13:54:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3809
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[20] => WP_Post Object
(
[ID] => 3786
[post_author] => 5
[post_date] => 2021-09-09 13:20:21
[post_date_gmt] => 2021-09-09 13:20:21
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2023-05-02 13:28:45
[post_modified_gmt] => 2023-05-02 13:28:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3786
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[21] => WP_Post Object
(
[ID] => 3696
[post_author] => 5
[post_date] => 2021-08-19 14:23:22
[post_date_gmt] => 2021-08-19 14:23:22
[post_content] =>
[post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ati-regeneron-covid-19-antibodies-manufacturing-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-15 07:52:58
[post_modified_gmt] => 2022-12-15 07:52:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3696
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[22] => WP_Post Object
(
[ID] => 3495
[post_author] => 5
[post_date] => 2021-08-10 13:06:45
[post_date_gmt] => 2021-08-10 13:06:45
[post_content] =>
[post_title] => US Department of Defense – Moderna, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => dod-moderna-covid-19-vaccine-supply-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-15 09:00:22
[post_modified_gmt] => 2022-12-15 09:00:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3495
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[23] => WP_Post Object
(
[ID] => 3414
[post_author] => 5
[post_date] => 2021-06-30 18:54:43
[post_date_gmt] => 2021-06-30 18:54:43
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-27 12:29:49
[post_modified_gmt] => 2022-06-27 12:29:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3414
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[24] => WP_Post Object
(
[ID] => 3352
[post_author] => 5
[post_date] => 2021-06-30 13:24:49
[post_date_gmt] => 2021-06-30 13:24:49
[post_content] =>
[post_title] => US Government - Ology Bioservices, COVID-19 Plasmid Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-12 13:47:30
[post_modified_gmt] => 2022-10-12 13:47:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3352
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[25] => WP_Post Object
(
[ID] => 3302
[post_author] => 6
[post_date] => 2021-06-30 09:21:45
[post_date_gmt] => 2021-06-30 09:21:45
[post_content] =>
[post_title] => UK Secretary of State - Roche, REGN-COV2 Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => 3302
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-15 09:07:23
[post_modified_gmt] => 2022-12-15 09:07:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3302
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[26] => WP_Post Object
(
[ID] => 3217
[post_author] => 6
[post_date] => 2021-06-28 12:14:37
[post_date_gmt] => 2021-06-28 12:14:37
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-15 09:11:47
[post_modified_gmt] => 2022-12-15 09:11:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3217
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[27] => WP_Post Object
(
[ID] => 3121
[post_author] => 6
[post_date] => 2021-06-03 14:26:32
[post_date_gmt] => 2021-06-03 14:26:32
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-15 09:13:08
[post_modified_gmt] => 2022-12-15 09:13:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3121
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[28] => WP_Post Object
(
[ID] => 2949
[post_author] => 6
[post_date] => 2021-05-28 18:52:06
[post_date_gmt] => 2021-05-28 18:52:06
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-15 09:37:27
[post_modified_gmt] => 2022-12-15 09:37:27
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2949
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[29] => WP_Post Object
(
[ID] => 2540
[post_author] => 5
[post_date] => 2021-03-12 18:12:48
[post_date_gmt] => 2021-03-12 18:12:48
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-15 09:38:53
[post_modified_gmt] => 2022-12-15 09:38:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2540
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[30] => WP_Post Object
(
[ID] => 2471
[post_author] => 5
[post_date] => 2021-01-25 13:08:02
[post_date_gmt] => 2021-01-25 13:08:02
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-15 09:39:40
[post_modified_gmt] => 2022-12-15 09:39:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2471
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[invalid_get] =>
[is_text_search] =>
[has_agreement_filters] =>
[has_any_agreement_filter] => Array
(
)
[found_agreements] =>
[has_provision_filters] => 1
[found_provisions] => 1
[lbl_quick_search:GHIAA2019\MapguideSearch:private] => Search results for:
[lbl_issue:GHIAA2019\MapguideSearch:private] => Issue:
[lbl_key_term:GHIAA2019\MapguideSearch:private] => Key Term:
[lbl_agreement_type:GHIAA2019\MapguideSearch:private] => Agreement Type:
[lbl_partner_type:GHIAA2019\MapguideSearch:private] => Partner Type:
[lbl_technology:GHIAA2019\MapguideSearch:private] => Technology:
[lbl_development_stage:GHIAA2019\MapguideSearch:private] => Development Stage:
[issues_by_id:GHIAA2019\MapguideSearch:private] => Array
(
[101] => WP_Term Object
(
[term_id] => 101
[name] => Access plans & principles
[slug] => equitable-access
[term_group] => 0
[term_taxonomy_id] => 101
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 31
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[100] => WP_Term Object
(
[term_id] => 100
[name] => Affordable pricing
[slug] => pricing
[term_group] => 0
[term_taxonomy_id] => 100
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 30
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[66] => WP_Term Object
(
[term_id] => 66
[name] => Benefit sharing
[slug] => benefit-revenue-sharing
[term_group] => 0
[term_taxonomy_id] => 66
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 10
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[53] => WP_Term Object
(
[term_id] => 53
[name] => Business model
[slug] => business-model
[term_group] => 0
[term_taxonomy_id] => 53
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[84] => WP_Term Object
(
[term_id] => 84
[name] => Confidentiality
[slug] => confidentiality
[term_group] => 0
[term_taxonomy_id] => 84
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 67
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[271] => WP_Term Object
(
[term_id] => 271
[name] => Donation
[slug] => donation
[term_group] => 0
[term_taxonomy_id] => 271
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 5
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[72] => WP_Term Object
(
[term_id] => 72
[name] => Effects of termination
[slug] => effect-of-termination
[term_group] => 0
[term_taxonomy_id] => 72
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 51
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[281] => WP_Term Object
(
[term_id] => 281
[name] => Ensuring continuity
[slug] => ensuring-continuity
[term_group] => 0
[term_taxonomy_id] => 281
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 35
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[46] => WP_Term Object
(
[term_id] => 46
[name] => Equitable Access
[slug] => access-to-medicines
[term_group] => 0
[term_taxonomy_id] => 46
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[278] => WP_Term Object
(
[term_id] => 278
[name] => Governance
[slug] => roles-responsibilities
[term_group] => 0
[term_taxonomy_id] => 278
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 53
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[80] => WP_Term Object
(
[term_id] => 80
[name] => Indemnification & liability
[slug] => indemnity
[term_group] => 0
[term_taxonomy_id] => 80
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 67
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[257] => WP_Term Object
(
[term_id] => 257
[name] => Information sharing
[slug] => information-sharing-information-sharing
[term_group] => 0
[term_taxonomy_id] => 257
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 57
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[109] => WP_Term Object
(
[term_id] => 109
[name] => Insurance
[slug] => insurance
[term_group] => 0
[term_taxonomy_id] => 109
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 37
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[48] => WP_Term Object
(
[term_id] => 48
[name] => Intellectual Property
[slug] => ip-ownership
[term_group] => 0
[term_taxonomy_id] => 48
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[50] => WP_Term Object
(
[term_id] => 50
[name] => Liability
[slug] => liability
[term_group] => 0
[term_taxonomy_id] => 50
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[88] => WP_Term Object
(
[term_id] => 88
[name] => License Grants
[slug] => license-grants
[term_group] => 0
[term_taxonomy_id] => 88
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 68
[filter] => raw
[parent_name] => Intellectual Property
[parent_slug] => ip-ownership
)
[87] => WP_Term Object
(
[term_id] => 87
[name] => Ownership of IP
[slug] => ownership-ip
[term_group] => 0
[term_taxonomy_id] => 87
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 55
[filter] => raw
[parent_name] => Intellectual Property
[parent_slug] => ip-ownership
)
[70] => WP_Term Object
(
[term_id] => 70
[name] => Payment Structures
[slug] => royalties-and-payments
[term_group] => 0
[term_taxonomy_id] => 70
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 52
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[102] => WP_Term Object
(
[term_id] => 102
[name] => Preparedness & response
[slug] => outbreak-preparedness
[term_group] => 0
[term_taxonomy_id] => 102
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 9
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[268] => WP_Term Object
(
[term_id] => 268
[name] => Product supply
[slug] => supply-purchase-of-products
[term_group] => 0
[term_taxonomy_id] => 268
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 31
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[49] => WP_Term Object
(
[term_id] => 49
[name] => Protecting & sharing information
[slug] => information-sharing
[term_group] => 0
[term_taxonomy_id] => 49
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[90] => WP_Term Object
(
[term_id] => 90
[name] => Protection of IP
[slug] => protection-results
[term_group] => 0
[term_taxonomy_id] => 90
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 44
[filter] => raw
[parent_name] => Intellectual Property
[parent_slug] => ip-ownership
)
[290] => WP_Term Object
(
[term_id] => 290
[name] => Publication of Results
[slug] => publication-of-results
[term_group] => 0
[term_taxonomy_id] => 290
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 41
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[56] => WP_Term Object
(
[term_id] => 56
[name] => Regulatory strategy
[slug] => regulatory-strategy
[term_group] => 0
[term_taxonomy_id] => 56
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 38
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[81] => WP_Term Object
(
[term_id] => 81
[name] => Representations & Warranties
[slug] => warranties
[term_group] => 0
[term_taxonomy_id] => 81
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 58
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[86] => WP_Term Object
(
[term_id] => 86
[name] => Technology transfer
[slug] => technology-transfer
[term_group] => 0
[term_taxonomy_id] => 86
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 26
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[52] => WP_Term Object
(
[term_id] => 52
[name] => Term & termination
[slug] => term-and-termination
[term_group] => 0
[term_taxonomy_id] => 52
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[76] => WP_Term Object
(
[term_id] => 76
[name] => Term of agreement
[slug] => term-of-agreement
[term_group] => 0
[term_taxonomy_id] => 76
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 55
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[74] => WP_Term Object
(
[term_id] => 74
[name] => Termination & withdrawal
[slug] => termination-and-withdrawal
[term_group] => 0
[term_taxonomy_id] => 74
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 53
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[282] => WP_Term Object
(
[term_id] => 282
[name] => Territory access commitments
[slug] => territory-access-commitments
[term_group] => 0
[term_taxonomy_id] => 282
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 35
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
)
[issues_by_slug:GHIAA2019\MapguideSearch:private] => Array
(
[equitable-access] => WP_Term Object
(
[term_id] => 101
[name] => Access plans & principles
[slug] => equitable-access
[term_group] => 0
[term_taxonomy_id] => 101
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 31
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[pricing] => WP_Term Object
(
[term_id] => 100
[name] => Affordable pricing
[slug] => pricing
[term_group] => 0
[term_taxonomy_id] => 100
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 30
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[benefit-revenue-sharing] => WP_Term Object
(
[term_id] => 66
[name] => Benefit sharing
[slug] => benefit-revenue-sharing
[term_group] => 0
[term_taxonomy_id] => 66
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 10
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[business-model] => WP_Term Object
(
[term_id] => 53
[name] => Business model
[slug] => business-model
[term_group] => 0
[term_taxonomy_id] => 53
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[confidentiality] => WP_Term Object
(
[term_id] => 84
[name] => Confidentiality
[slug] => confidentiality
[term_group] => 0
[term_taxonomy_id] => 84
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 67
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[donation] => WP_Term Object
(
[term_id] => 271
[name] => Donation
[slug] => donation
[term_group] => 0
[term_taxonomy_id] => 271
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 5
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[effect-of-termination] => WP_Term Object
(
[term_id] => 72
[name] => Effects of termination
[slug] => effect-of-termination
[term_group] => 0
[term_taxonomy_id] => 72
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 51
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[ensuring-continuity] => WP_Term Object
(
[term_id] => 281
[name] => Ensuring continuity
[slug] => ensuring-continuity
[term_group] => 0
[term_taxonomy_id] => 281
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 35
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[access-to-medicines] => WP_Term Object
(
[term_id] => 46
[name] => Equitable Access
[slug] => access-to-medicines
[term_group] => 0
[term_taxonomy_id] => 46
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[roles-responsibilities] => WP_Term Object
(
[term_id] => 278
[name] => Governance
[slug] => roles-responsibilities
[term_group] => 0
[term_taxonomy_id] => 278
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 53
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[indemnity] => WP_Term Object
(
[term_id] => 80
[name] => Indemnification & liability
[slug] => indemnity
[term_group] => 0
[term_taxonomy_id] => 80
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 67
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[information-sharing-information-sharing] => WP_Term Object
(
[term_id] => 257
[name] => Information sharing
[slug] => information-sharing-information-sharing
[term_group] => 0
[term_taxonomy_id] => 257
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 57
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[insurance] => WP_Term Object
(
[term_id] => 109
[name] => Insurance
[slug] => insurance
[term_group] => 0
[term_taxonomy_id] => 109
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 37
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[ip-ownership] => WP_Term Object
(
[term_id] => 48
[name] => Intellectual Property
[slug] => ip-ownership
[term_group] => 0
[term_taxonomy_id] => 48
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[liability] => WP_Term Object
(
[term_id] => 50
[name] => Liability
[slug] => liability
[term_group] => 0
[term_taxonomy_id] => 50
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[license-grants] => WP_Term Object
(
[term_id] => 88
[name] => License Grants
[slug] => license-grants
[term_group] => 0
[term_taxonomy_id] => 88
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 68
[filter] => raw
[parent_name] => Intellectual Property
[parent_slug] => ip-ownership
)
[ownership-ip] => WP_Term Object
(
[term_id] => 87
[name] => Ownership of IP
[slug] => ownership-ip
[term_group] => 0
[term_taxonomy_id] => 87
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 55
[filter] => raw
[parent_name] => Intellectual Property
[parent_slug] => ip-ownership
)
[royalties-and-payments] => WP_Term Object
(
[term_id] => 70
[name] => Payment Structures
[slug] => royalties-and-payments
[term_group] => 0
[term_taxonomy_id] => 70
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 52
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[outbreak-preparedness] => WP_Term Object
(
[term_id] => 102
[name] => Preparedness & response
[slug] => outbreak-preparedness
[term_group] => 0
[term_taxonomy_id] => 102
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 9
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[supply-purchase-of-products] => WP_Term Object
(
[term_id] => 268
[name] => Product supply
[slug] => supply-purchase-of-products
[term_group] => 0
[term_taxonomy_id] => 268
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 31
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[information-sharing] => WP_Term Object
(
[term_id] => 49
[name] => Protecting & sharing information
[slug] => information-sharing
[term_group] => 0
[term_taxonomy_id] => 49
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[protection-results] => WP_Term Object
(
[term_id] => 90
[name] => Protection of IP
[slug] => protection-results
[term_group] => 0
[term_taxonomy_id] => 90
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 44
[filter] => raw
[parent_name] => Intellectual Property
[parent_slug] => ip-ownership
)
[publication-of-results] => WP_Term Object
(
[term_id] => 290
[name] => Publication of Results
[slug] => publication-of-results
[term_group] => 0
[term_taxonomy_id] => 290
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 41
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[regulatory-strategy] => WP_Term Object
(
[term_id] => 56
[name] => Regulatory strategy
[slug] => regulatory-strategy
[term_group] => 0
[term_taxonomy_id] => 56
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 38
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[warranties] => WP_Term Object
(
[term_id] => 81
[name] => Representations & Warranties
[slug] => warranties
[term_group] => 0
[term_taxonomy_id] => 81
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 58
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[technology-transfer] => WP_Term Object
(
[term_id] => 86
[name] => Technology transfer
[slug] => technology-transfer
[term_group] => 0
[term_taxonomy_id] => 86
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 26
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[term-and-termination] => WP_Term Object
(
[term_id] => 52
[name] => Term & termination
[slug] => term-and-termination
[term_group] => 0
[term_taxonomy_id] => 52
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[term-of-agreement] => WP_Term Object
(
[term_id] => 76
[name] => Term of agreement
[slug] => term-of-agreement
[term_group] => 0
[term_taxonomy_id] => 76
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 55
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[termination-and-withdrawal] => WP_Term Object
(
[term_id] => 74
[name] => Termination & withdrawal
[slug] => termination-and-withdrawal
[term_group] => 0
[term_taxonomy_id] => 74
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 53
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[territory-access-commitments] => WP_Term Object
(
[term_id] => 282
[name] => Territory access commitments
[slug] => territory-access-commitments
[term_group] => 0
[term_taxonomy_id] => 282
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 35
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
)
[filter_issues:GHIAA2019\MapguideSearch:private] => Array
(
[0] => supply-purchase-of-products
)
)
